Moderna reports first positive Phase 3 for mRNA neoantigen therapy in melanoma
Moderna and Merck have reported positive Phase 3 clinical trial results for an individualized mRNA cancer therapy used in combination with Keytruda for melanoma patients. This marks the first successful Phase 3 trial for an mRNA-based cancer treatment, demonstrating improved recurrence-free survival rates.
Why it matters
This milestone validates the potential of mRNA technology beyond vaccines, opening new frontiers in personalized oncology and cancer treatment.
Noubar Afeyan on X: "Today marks an important milestone for @moderna_tx , for the field of mRNA, and for the many people working to bring new possibilities to patients. This morning, Moderna and Merck announced positive Phase 3 results for adjuvant treatment with intismeran autogene, an" / X
Noubar Afeyan on X: "Today marks an important milestone for @moderna_tx , for the field of mRNA, and for the many people working to bring new possibilities to patients. This morning, Moderna and Merck announced positive Phase 3 results for adjuvant treatment with intismeran autogene, an"
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in